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Cell surface proteoglycans (PGs) are key molecules in the regulation of tumour progression and 
metastasis formation. Eleven primary surface PGs, including syndecans-1-4, glypicans-1-6 and 
NG2, are currently known to act as mediators of the cancer cell’s interaction with the host 
microenvironment, with the potential to function synergically or antagonistically in the promotion of 
tumour growth and spreading. Using soft-tissue sarcomas as a model system we have observed 
that a given tumour cell may constitutively and coincidently express on average 3-5 of the 11 
surface PGs, suggesting that diverse combinations of surface PGs may dictate the behaviour of 
cancer cells in different manners. To start to investigate the PG surface profiles as pro- and anti-
tumorigenic we delineated strategies to modify the PG expression of 143B osteosarcoma cells by 
stable gene transduction and by examining how these modifications affected the cells adhesive 
and migratory capabilities in response to selected ECM substrates, and endothelial monolayers. To 
date there are no notice about GPC6 implications either in cell-ECM interactions or in the 
behaviour motility of cells. For these reasons 143B cells were stable transfected for overexpressing 
GPC6 showed a modulation of relative expression of all surface PGs respect to vector control 
cells. GPC6 overexpression induces morphological modification in 143B cells which are seen as 
changes in the organization of actin filaments containing protrusions similar to 
fillopodia/lamellipodia and an increase of motility cells in monodimensional assay which could be in 
relationship with cytoskelatal reorganization. Moreover these cells showed a spreading ability and 
the lower invasion ability on different ECM molecules that could be correlated by surface PG profile 
modulation. Since NG2 as a cell surface ligand for collagen type VI has been postulated to be 
involved in tumor progression, we have also examinated the interaction of the NG2+ and NG2- 
sarcoma cells with collagen type VI and other ECM molecules. Sarcoma cells were NG2 abrogated 
by RNAi or cells immunosorted for NG2 expression were found to exhibit a rather elective, 
impaired ability to adhere and migrate on purified collagen type VI. These findings confirmed that 
the NG2 was capable of mediating tumour cell adhesion and migration through interaction with this 
specific collagen. The outcome of these investigations provide a first evidence that NG2 may 
represent a unique, malignancy promoting factor in several types of soft-tissue sarcomas and that 
defined surface PGs pattern differentially control tumour progression, with some profiles being 
specifically associated with an aggressive behaviour, whereas others with a more benign 
phenotype. 
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1.1. Proteoglycans (PGs) 
Proteoglycans (PGs) are glycoproteins that can be found on the cell surface and 
extracellular matrix (ECM) where they mediate critical interactions between cells and their 
environment. They consist of a core protein with one or more covalently attached 
glycosaminoglycan (GAG) chain(s). PGs are classified both on the basis of their 
localization and on the type of the core protein and GAG-chain composition (Fig. 1).  
 
 
Heparan sulphate (HS) and chondroitin sulphate (CS) chains are bound to membrane 
associated PGs such as glypicans, syndecans and NG2. PGs found in the extracellular 
matrix (ECM) may also carry keratin (KS) and dermatan sulphate (DS) GAG chains.  
Next to collagens, PGs constitute a major class of extracellular matrix (ECM)/cell surface 
components known to be involved in both primary physiological and pathological 
phenomena. In vertebrates, PGs are among the first ECM constituents to be produced 
during embryonic development and are often aberrantly expressed in a variety of inherited 
and acquired disorders. Surface expression of certain PGs also appears to be an early 
embryonic event and, paradoxically, due to the altered transcription/translation patterns 
that these PGs exhibit, they have been identified as potential diagnostic/prognostic and 
therapeutic targets in diverse disease states. Several cell surface-associated PGs, and at 
least one ECM PG, are widely expressed throughout embryonic and adult life of 
invertebrates, underscoring the highly evolutionary conserved nature of these 
Figure 1. Simplified diagram showing the major PG families.  
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macromolecules and their multivalent biological role. Based upon its direct involvement in 
cell–cell and cell–ECM interactions, this gene family has been strongly implicated in the 
regulation of cell movement (Table 1)  
 
Table 1. Predicted functional traits of PGs involved in the regulation of cell movement1 (From Cattaruzza and Perris, 2005) 
 
PROTEOGLYCAN 
 
Haptotactic 
ECM 
component2 
 
Non 
permissive 
directional 
cue3 
 
 
ECM 
linker of 
direction-
promoting 
cues4 
 
Shedded 
motility-
promoting 
factor5 
 
Cryptic 
motility-
promoting 
factor6 
 
Shedded 
motility-
inhibitor7 
 
Cell 
surface 
interactor8 
 
 
 
Enhancer of 
signal 
transduction9 
 
 
 
Cell-ECM 
co-
receptor10 
 
 
 
Versican V0-V2 
 
X 
  
 
  
(X) 
  
X 
 
 
 
 
Versican V3 
 X      (X)  
Aggrecan 
 X X       
Neurocan 
 X X       
Brevican (X) X X       
CD44 
     (X) X X X 
Perlecan 
 X X  X     
Decorin 
 X X       
Biglycan 
 X        
Fibromodulin 
 X        
Keratokan 
 X        
Lumican (X) X        
NG2 
     (X) X X X 
Syndecan-1 
     X X X X 
Syndecan-2 
     X X X X 
Syndecan-3 
     (X)  (X) X 
Syndecan-4 
     (X) X X X 
Glypican-1 
      X   
Glypican-2 
 X X    X  X 
Glypican-3 
     X X   
TENB2 
      X   
Neuroglycan-C 
 X        
Phosphocan 
 X     X  X 
1Based upon both published and unpublished observations; 
2Acting alone or in combination with other ECM components as a haptotactic motility factor; 
3Regulator of directionality of cell migration by acting as a non-permissive ECM substrate component; 
4Capable of sequestering chemotactic molecules and cell growth- and motility-promoting factors in the ECM; 
5Enhancer of cell motility when shedded from the cell surface; 
6Promoter of cell motility following proteolysis; 
7Acting as motility-inhibiting factor when shedded from the cell surface; 
8Engaded in multivalent interactions with cell surface components directly or indirectly involved in the control of cell motility; 
9Directly mediating signal transduction cascades involved in the regulation of cell movement; 
10Specifically serving as co-receptor for ECM components and thereby implicated in the regulation of cell movement. 
 
However, how PGs actually affect this process is only partially understood and in some 
instances controversial. It is currently believed that both normal and tumour cells may 
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adapt their modality of locomotion according to the environment through which they 
migrate and by adjusting their migratory strategy from ‘‘path generating’’ to ‘‘path finding’’. 
To accomplish this, cells co-ordinately rearrange the surface organization of integrins, 
PGs, cell adhesion molecules, and membrane-bound metalloproteinases (Wolf et al., 
2003). Thus, intricate patterns of cooperation between PGs and other cell surface 
components may be envisioned and the dissection of these interplays is fundamental to 
understand how cell movement is regulated 
 
1.2 .  Membrane-associated proteoglycans 
In the last year cell surface PGs have been at the centre of numerous studies because of 
their multifunctional nature. Some PG core proteins have transmembrane and 
cytoplasmatic domains, such as syndecans and NG2 forming direct molecular linkages 
between the extracellular and intracellular environments. Whereas glypicans are linked to 
the plasma membrane with glycosylphosphatidylinositol (GPI)-anchor, suggesting that 
these molecules may function in concert with changes in phospholipids metabolism and 
signalling (Fig. 2). 
 
Figure 2. Three main classes of cell-surface PG. Syndecans and glypicans structure with HS chains. Syndecans can also 
contain a chondroitin sulphate (CS) chain(s). While NG2 proteoglycan can contain only CS chains. 
 
Glypicans and syndecans are heparan sulphate proteoglycans (HSPGs) and their core 
proteins (40-70KDa) are linked to HS GAG chains characterized by alternating of N-acetyl 
glucosamine (GlcNAc) and glucuronic (GlcA) or iduronic acid residues (Bernfield et al., 
1999). These HS chains are responsible for much of the HSPGs biological roles and the 
core proteins have evolved to maximize their efficiency in these roles. NG2 with a core 
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protein of 550 and a size of the full molecule of 600KDa is a unique chondroitin sulphate 
transmembrane proteoglycan, characterized of alternating sugars (N-acetylgalactosamine 
(GalNAc) and glucuronic acid. Unlike to HSPGs, NG2 PGs core protein can be expressed 
on the cell surface either with or without chondroitin sulphate GAG chains, placing NG2 in 
the category of part-time proteoglycans (Stallcup et al., 1990). Membrane PGs regulate 
the distribution of extracellular signalling molecules such as morphogens and chemokines, 
and modulate signalling events at the cell surface that influence cell fate determination, 
proliferation, adhesion and motility. They participate in endocytosis and vesicular 
trafficking, regulating the movement of molecules between intracellular and extracellular 
compartments. Several of them have assumed important roles as prognostic factors 
and a few of them are now contemplated for therapeutic applications. Literature data 
and our preliminary observations indicate that given tumour cells may constitutively 
and coincidently express on average 3-5 surface PGs, suggesting that given 
combinations of surface PGs may diversely dictate the behaviour of cancer cells, 
during distinct phases of tumour progression. 
 
 
 
1.3. Syndecans 
Syndecans are transmembrane heparan sulphate and comprise a family of four distinct 
genes: SDC1, 2, 3 and 4. Their chromosomal locations, exon organization, and sequence 
relationships with the single Drosophila syndecan (D syndecan) suggest that the gene 
family arose by gene duplication and divergent evolution from a single ancestral gene, 
and that SDC-1 and SDC3 and SDC2 and SDC4 represent subfamilies (Bernfield et 
al.1999; Fig. 3). Each gene product is a single type I membrane-spanning protein with an 
apparently extended extracellular domain of variable size that contains covalently 
attached HS chains distal from the plasma membrane. 
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Figure 3. Dendrogram suggests that the D-Sdc gene is derived from a common ancestor of the four 
mammalian syndecan genes and that SDC1 and Synd3 form one subfamily and SDC2 and SDC4 form 
another. (Modified from Spring et. ,1994) 
 
Syndecan core proteins (40-50 KDa) contain three different functional domains: the 
extracellular, cytoplasmatic and transmembrane domain. The extracellular domain 
(ectodomain) is among the most rapidly diverging vertebrate proteins with the exception of 
their regions for GAG attachment, cell interaction, proteolytic cleavage, and 
oligomerization. Ectodomain contains two regions for GAGs attachment (Esko et al., 
1996; Bourdon et al., 1989). SDC1, 3 and 4 also contain Ser-Gly sequence near the 
plasma membrane that may serve as attachment sites for CS (Kokenyesi et al., 1994). 
Transmembrane domain is evolutionarily relatively stable and only a few amino acids 
differ among the vertebrate sequences. It contains the regions for interactions with other 
membrane proteins and for localization to distinct membrane compartments. 
Transmembrane domain may also interact within the plane of the membrane with proteins 
involved in cell spreading, sensitive to protein tyrosine kinase inhibitors (Lebakken et al, 
1996). Despite of the molecular volume of their HS chain it is possible to find these PGs in 
oligomers form, especially in dimmers. Both syndecans bearing small HS chains (i.e. 
produced by keratinocytes) and syndecans devoid of HS chains are inclined to form 
oligomers Sanderson et al., 1992). Oligomerization would enhance the proximity between 
syndecan core proteins, enlarging their interaction surface, and increasing the probability 
of interaction with other membrane proteins (Klemm et al, 1998). The cytplasmatic 
domains contain two invariant regions, a membrane proximal common region (C1) 
containing a serine and a tyrosine and a C-terminal common region (C2), separated by a 
region (V) of variable length and composition. The C2 region shows an EFYA sequence at 
the C-terminus that can bind to the PDZ domains present in intracellular proteins. PDZ 
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domains organize and assemble protein complexes on the inner surface of the plasma 
membrane and are thought to link membrane components to the underlying actin-
containing cytoskeleton. The variable (V) region is distinct for each of the 4 family 
members, suggesting functional difference between these PGs (Bernfield et al., 1999). 
The function of this domain is largely unknown except for SDC4, where it is responsible 
for the assembly of SDC4 tetramers with phosphatidylinositol 4,5-bisphosphate (PIP2) 
and activated protein kinase C-α (PKC-α) in focal adhesions (Woods et al, 2001; 
Rapraeger et al., 1998). Instead SDC2 V region serve only as substrata for PCKα (Itano et 
al., 1996)  Syndecans can be involved in growth control, cell spreading, cellular 
recognition, cellular adhesion, and signalling and. Their function as co-receptors with 
integrins and cell-cell adhesion molecules (fibronectin, vitronectin, laminins, and the 
fibrillar collagens; Bernfield et al, 1999; Thodeti et al., 2003). All syndecans studied can be 
shed from the cell surface by proteolytic cleavage near the plasma membrane (Fitzgerald 
et al., 2000). Shedding of the syndecan ectodomains is highly regulated and can be 
accelerated by various cellular effectors (thrombin and plasmin), which, interestingly, do 
not usually bind HS. Syndecans expression levels are regulated during development in 
morphogenesis, cell differentiation and they can be altered in tumorigenesis, progression 
and metastasis process (Sanderson et al., 2001).  
 
1.4. Glypicans 
The first member of the family of GPI-anchored heparan sulphate (HS)-substituted PGs, 
later named glypicans (GPC), was identified some 15 years ago (David G. et al., 1990). 
Glypicans comprise a family of at least six distinct genes in mammals GPC-1,-2,-3,-4,-5,-6 
(Filmus 1998, Watanabe 1995 ) two in Drosophila, called Dally and Dally-like (Nakato et 
al., 1995; Baeg et al., 2001) and one C. elegans, called knypek (Fransson et al. 2004). All 
glypicans have an N-terminal signal sequence; an ~60-70 kDa globular domain with a 
characteristic pattern of 14 highly conserved cysteine residues (CRD region), with the HS 
attachment sites; and finally a C-terminal sequence involved in formation of a GPI for 
linking to the plasma membrane. Except for the HS attachment sequences, the HS-
bearing juxtamembrane regions are the most divergent sequences in glypican core 
proteins (Bernfield et al., 1999). The structures of each glypican are extremely well 
conserved across species (more than 90% identical when comparing glypicans from 
different vertebrate species; Fig. 4).  
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Figura 4. Diagrams showing the derived core protein domain organization, locations of putative GAG attachment sites, 
dendrogram and aligned sequences of human glypican-1 through -6 and dally, the Drosophila glypican homolog (from 
Bernfield 1999) 
 
The hypothesis of different subfamilies is further strengthened by an analysis of the 
genomic structures of the corresponding genes as follows: GPC1, GPC2, GPC4, and 
GPC6 consist of nine exons, whereas GPC3 and GPC5 contain only eight exons 
(Veugelers et al., 1998; Huber et al., 1997). The GPC1, 2, 4, and 6 form a separate group 
with high homology (40–60%) to each other but only 20% identity to the other group 
comprising GPC3 and GPC5 (also 40% identical to each other). Interestingly, GPC6 is 
most homologous to GPC4 (both proteins are 63% identical). This suggests glypicans 
arose from a series of gene and genome duplications and may herald extension of the 
gene family by additional members and gene clusters (Bernfield et al., 1999). Whether 
members of the same subfamily share some common functions and members belonging 
to different subfamilies have different functions remains to be established. Glypicans are 
linked to membrane lipid without penetring the bilayer. Currently, the functional 
significance of attaching proteins through a GPI anchor has not been clearly established. 
One of these possible roles is the targeting of GPI-anchored proteins to specific micro-
domains within the cell membrane called ‘rafts’ (Brown et al., 1992) that can facilitate 
interactions with specific intracellular signalling molecules in the absence of a cytoplasmic 
domain (Ilangumuran et.al., 2000). GPI anchors may also be to provide a system of 
regulated release of proteins to the extracellular environment with releasing from cell 
surfaces by proteolytic cleavage and by the action of a phosphatidyl inositol-specific 
phospholipase C (Ishihara et al, 1997). Moreover, the anchor is reported to mediate the 
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turnover of cell surface components by rapid endocytosis and transport to lysosomes 
(Yanagashita et al., 1998). In general, glypicans are expressed predominantly during 
development (De Cat et al., 2001), the expression levels have been shown to change in a 
stage- and tissue-specific manner suggesting that glypicans are involved in 
morphogenesis (Saunders et al.,1998; Pellegrini et al.,1998; De Cat et al.,2001; Table 2)  
 
Table 2. The glypican family during embryogenesis and in adult tissues (adapted from Fico et al., 2007). 
 
In general, glypicans interaction of with multiple proteins may be due to the fact that the 
length and modifications of the heparan sulphate chains are cell-type-specific (Nurcombe 
et al., 1993). It has also be seen that Glypicans regulate the signalling of morphogenesis 
through Wnt, Hedgehog (Hh), bone morphogenetic proteins (BMPs), and fibroblast growth 
factors (FGFs; Yayon et al., 1991). In fact GPC1 and GPC3 are able to sequester a 
variety of growth in particular they can link TGFβ, BMP and Wnt family controlling their 
signalling events. Consistent with a proposed role in development, the expression 
patterns of these glypicans often coincide with those of growth factors, such as FGFs and 
BMPs and their receptors (Veugelers et al., 1999).  
 
 
1.5. GPC6 
Till 1999 five members of the glypican family have been identified in vertebrates. Bio-
informatics analyses have led to the identification of a sixth member of the human 
glypican gene family and of its mouse orthologue. As might have been expected from the 
characterization of the other members, the human and mouse forms of Gpc-6 are highly 
Name Original 
Designation 
Expression in 
Embryo 
Expression in 
Adult 
Reference 
Glypican 1  Glypican  Bone, bone marrow, 
muscle epidermis, 
kidney  
Most tissues  David et al., 1990; 
Litwack et al., 1994  
Glypican 2  Cerebroglycan  Nervous system  Not detected  Stipp et al., 1994; Ivins 
et al., 1997  
Glypican 3  OCI-5  Most tissues  Ovary, mammary 
gland, mesothelium, 
lung, kidney  
Filmus et al., 1998; 
Pellegrini et al., 1998; 
Li et al., 1997; Filmus 
(unpublished 
observations)  
Glypican 4  K-glypican  Brain, kidney, lung  Most tissues  Watanabe et al., 1995; 
Veugelers et al., 1998; 
Siebertz et al., 1999  
Glypican 5  Brain, lung, 
liver, kidney, 
limb  
Brain  Veugelers et al., 
1997; Saunders et 
al., 1997  
 
Glypican 6  Many tissues, 
including liver 
and kidney  
Many tissues including 
ovary, kidney, liver, and 
intestine  
Paine-Saunders et 
al., 1999; Veugelers 
et al., 1999  
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similar in structure, with 96% identity (Fig. 5). Besides GPC6 is high similar to GPC4 with 
63% identity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on similarities in sequence and gene organization, GPC1, 2, 4, and 6 appear to 
define a subfamily of glypicans, differing from the subfamily comprising so far GPC3 and 
GPC5. The GPC6 gene maps close to the GPC5 gene on human chromosome 13q32, 
whereas GPC4 maps to chromosome Xq26, where it flanks GPC3, the gene encoding the 
glypican which so far is most homologous to GPC5. Northern blotting indicates that GPC6 
mRNA is widespread, with prominent expressions in human fetal kidney and adult ovary. 
In situ hybridization studies localize GPC6 to mesenchymal tissues in the developing 
mouse embryo (Sanderson at al., 1996). High expressions occur in smooth muscle cells 
lining the aorta and other major blood vessels and in mesenchymal cells of the intestine, 
kidney, lung, tooth, and gonad (Veuglers et al.,1999). There is no evidence about 
molecular interaction of GPC6 in cell spreading and cell invasion, so GPC6 was 
overexpressed in sarcoma cells for studying its involvement in adhesion and migration of 
cells. 
 
1.6. NG2/CSPG4 
NG2 is a chondroitin sulphate (CS) membrane-spanning protein that interacts with 
macromolecules on both sides of the plasma membrane. NG2 has an extensive 
extracellular domain of 2195 amino acids and a much smaller cytoplasmic domain of 76 
amino acids. A single 25-residue transmembrane domain divides the core protein into a 
relatively short 76 amino acid cytoplasmic tail and an extensive 2225-residue extracellular 
domain (Fig. 6). 
Figure 5. The lengths of the lines in this tree are directly proportional to the predicted genetic distances between 
individual sequences. These results indicate that glypican-4 and glypican-6 are in fact more closely related than any 
other pair of vertebrate glypicans previously described. 
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Figure 6. The N-terminal globular domain 1 is stabilized by intramolecular disulfide bonds (the actual number of disulfides is 
not known). The central domain 2 contains both the type VI collagen-binding site and the single chondroitin sulphate chain 
(irregular line). The membrane-proximal globular domain 3 contains at least two sites for proteolytic processing of NG2. The 
cytoplasmic tail contains a PDZ-binding motif a proline-rich segment, and several potential sites for threonine 
phosphorylation . 
 
The extracellular domain of the NG2 core protein contains three subdomains: an N-
terminal globular domain (domain 1), a central extended domain that has the sites for GAG 
attachment (domain 2), and a juxtamembrane domain (domain 3). Domain 1 has a 
globular conformation stabilized by intramolecular disulphide bonds (Tillet et al., 1997; 
Burg et al., 1997); domain 2 contains the sites for binding CS chains (Stallcup et al, 2001) 
and it contains α-helical site for collagen type V and VI binding (Tillet, 1997; Burg 1997); 
domain 3 is the globular juxtamembrane site for proteolysis of NG2 that leads to its 
cleavage and release from the cell surface (Stallcup et al, 2001). At the extreme C-
terminus, a QYWV sequence fits the pattern for a PDZ-binding motif (Songyang et al., 
1997) and may be responsible for interaction of NG2 with MUPP1, a multi- PDZ domain-
containing cytoplasmic scaffolding protein (Barritt et al., 2000). NG2 is expressed by 
immature progenitor cells in several different developmental lineages, including 
oligodendrocyte progenitors, chondroblasts, and pericytes/smooth muscle cells 
(Nishiyama et al., 1991; Grako et al., 1995; 1999; Burg et al., 1999; Schlingemann et al., 
1990). The expression pattern of NG2 on immature progenitor cells suggested that the 
NG2 might contribute to processes such as cell proliferation and motility which are critical 
to progenitor biology. In fact NG2 is often re-expressed by tumour cells, which are usually 
characterized by increased proliferation and migration. 
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1.7. Metastasis 
Tumour cell invasion and metastasis is highly dependent on dynamic changes in the 
adhesion and migration of transformed and malignant cells. Tumour metastasis consists 
of a series of biological processes that move tumour cells from the primary neoplasm to a 
distant location (Fig. 7). 
 
 
 
Figure 7. The tumour metastatic process (From Patricia S Steeg, 2006) 
 
At the primary tumour site, tumor cells invade into the lymphatics or directly into the 
circulation. Once in the bloodstream, tumour cells must survive and avoid immune attack 
to extravasate. Arrest is most often by size restriction in capillary beds but can involve 
specific adhesive interactions. The process by which tumour cells form micrometastases 
and then progressively growing, vascularized macrometastases in a distant organ is 
termed metastatic colonization. Metastatic colonization involves reciprocal interactions 
between tumour cells and the microenvironment of the distant organ, and can pause for 
periods of dormancy. One of the most enduring observations in metastasis research was 
published in 1889 by Stephen Paget. Describing tumour cells as the “seed” and the host 
environment as the “soil,” Paget hypothesized that their interaction determines metastatic 
outcome: “When a plant goes to seed, its seeds are carried in all directions; but they can 
only live and grow if they fall on congenial soil”. This observation predicted that the tissue 
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environment, composed of a myriad of specialized cell types, extracellular matrices and 
cells recruited to the site, may facilitate tumour metastasis and contribute to the organ 
selectivity sometimes seen in metastatic colonization. Complex and redundant pathways 
involving the tumour cell and the microenvironment mediate tumour invasion at the 
primary site, survival and arrest in the bloodstream, and progressive outgrowth at a distant 
site.  
Understanding these pathways and their dynamic interactions will help identify promising 
molecular targets for cancer therapy and key obstacles to their clinical development.  
 
1.8. Soft Tissue Sarcoma (STS) 
Sarcomas are a heterogeneous group of rare tumours that arise predominantly from the 
embryonic mesoderm. The various sarcomas include bone sarcomas (osteosarcomas and 
chondrosarcomas), Ewing’s sarcomas, peripheral primitive neuroectodermal tumours, and 
soft tissue sarcomas, which are the most frequent. In 2004, approximately 8,680 new 
cases are expected to be diagnosed in the United States, and 3,660 deaths from soft 
tissue sarcomas are predicted, accounting for 0.63% of all cases and 1.15% of deaths 
from cancer (Jemal et al, 2004). Currently, more than 50 histologic types of soft tissue 
sarcoma have been identified (Table 3), but the most common are malignant fibrous 
histiocytoma (28%), leiomyosarcoma (12%), liposarcoma (15%), synovial sarcoma (10%), 
and malignant peripheral nerve sheath tumours (6%; Coindre et al., 2001). 
Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. 
 
         Table 3. Histologic Subtypes of Soft Tissue Sarcoma 
Histological Subtypes n % 
Malignant Fibrous Histiocytoma  349 28 
Liposarcoma 188 15 
Leiomyosarcoma 148 12 
Unclassified sarcoma 140 11 
Synovial sarcoma 125 10 
Malignant Peripheral Nerve Shealth Tumor 72 6 
Rhabdomyosarcoma 60 5 
Fibrosarcoma 38 3 
Ewing’s Sarcoma 25 2 
Angiosarcoma 25 2 
Osteosarcoma 14 1 
Ephiteliod Sarcoma 14 1 
Chondrosarcoma 13 1 
Clear cell Sarcoma 12 1 
Alveolar Soft Part Sarcoma 7 1 
Malignant Hemangiopericytoma 5 0,5 
         Modified from Coindre et al. 
 
As for most types of tumours, the presence of metastasis at diagnosis, or the evolving of 
such lesions with time, catastrophically reduces the probability of survival. Factors 
predicting the formation of metastasis in soft-tissue sarcoma patients are not known and 
similarly obscure remains the modes through which metastases form in these individuals. 
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1.9. Membrane PGs and tumour 
One of the most classical experiments demonstrating the importance of cell surface PGs 
in tumour progression, and in particular the role of HS-carrying PGs, was originally 
performed by Jeffrey Esko and collaborators (Esko et al., 1988). This study highlighted 
that cells genetically engineered to be defective in the HS biosynthesis, and thereby 
harbouring a compositional deficit of their surface HSPGs, failed to form tumours both in 
vitro and in vivo. These findings were strongly corroborated by comparative analyses of 
the GAG structures present on the surface of tumour cells with different metastatic 
potentials (Cattaruzza et al., 2005). In most solid tumours, especially those of epithelial 
origin, clinically orientated surveys have shown a certain prognostic correlation between 
the overall levels of surface PGs expression and disease-free survival (Table 4).  
 
Table 4. Potential clinical applications of membrane proteoglycans in the field of oncology (358 papers; 1990-2007)  
PG Diagnostic Predictive/prognostic 
SDC1/CD138 Mesothelioma Carcinoma:   breast, oral squamous cell, 
pancreatic, cervical, small cell 
lung, prostate, ovarian 
Hodgkin’s lymphoma 
Myeloma 
PEL 
Endometrial cancer 
Intrahepatic cholangiocarcinoma 
Mesothelioma 
Syndecan-2 Mesothelioma ? 
Syndecan-3 ? ? 
Syndecan-4 ? ? 
GPC-1 ? Pancreatic carcinoma 
GPC-2 ?  
GPC-3 Hepatocarcinoma 
(Melanoma) 
Hepatocarcinoma 
GPC-4 ? ? 
GPC-5 ? ? 
GPC-6 ? ? 
NG2 MLL ALL ? 
 
With the possible exception of breast carcinoma, the initial dysplastic phases of epithelial 
tumorigenic involve a pronounced loss of syndecan surface expression, which occurs at 
both transcriptional and translational level and is believed to be a prerequisite to attain a 
migratory phenotype (Matsumoto et al., 1997; Day et al., 1999). Subsequently, an 
accumulation of syndecans in the stromal compartment accompanies an enhanced 
invasiveness of the malignant cells and a poor prognosis (Bayer-Garner et al., 2000; 
Wicksten et al., 2001; Zellweger et al., 2003; Barbareschi et al., 2003; Leivonen et al., 
2004). Of the four syndecan family members, SDC1 (Fig. 8) is the most extensively 
studied and was the first HSPG to be identified and cloned. SDC1 is down regulated in a 
variety of cancer tissues (Wiksten, J. P, 2001, Nakanishi, K, 1999) and the loss of SDC1 
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expression renders the tumour cells less adhesive, thereby increasing their potential to 
metastasize. Instead augmented SDC1 expression is a hallmark of malignancy in multiple 
myeloma, several types of lymphomas and certain leukaemia. In B cell lymphomas, cell 
surface-bound SDC1 assists the cells in their spreading, cytoskeletal reorganization and 
signal transduction (Lebakken et al., 2000; McQuade and Rapraeger, 2003). This since, in 
these pathological entities, SDC1 expression seems to inhibit cell–ECM interactions, 
haptotactic motility and invasion of three-dimensional matrices/cell monolayers 
(Liebersbach and Sanderson, 1994; Liu et al., 1998; Langford et al., 2005; Spessotto et 
al., 2001), while favouring cell–cell adhesions through a re-targeted cell surface 
redistribution to uropods of polarized cells (Børset et al., 2000). 
 
Conversely, SDC2 seems to be a characterizing constitutive component of metastatic 
colon and lung carcinoma cells, where it contributes, alone, or in cooperation with SDC4, 
to their recognition and stabilization of contacts with ECM molecules serving as potent 
migratory substrates (Kusano et al., 2000; Contreras et al., 2001; Park et al., 2002; 
Munesue et al., 2002). The role of SDC2 in cell migration has been less investigated, but 
several reports indicate that it may positively regulate cell migration, since it is normally 
highly expressed in cells on migratory conditions (Fig. 9). Upregulation of SDC4 has been 
noted in hepatocellular carcinomas and malignant mesotheliomas and this over 
expression may correlate with increased tumour cell proliferation (Beauvais et al., 2004). 
 
Figure 8. Schematic overview of the putative molecular functions of SDC1. Through its HS chains and core protein the PG 
may link to ECM components and cooperate with integrins in cell-ECM interactions and/or form oligomeric complexes 
activating integrin-independent cytoskeletal rearrangements and signal transduction. SDC1 molecules are also 
endocytosed and recycled through specific pathways that coincidently may activate additional signal transduction events. 
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The role of SDC3 is much less know/studied. SDC3 plays an important role in regulation 
of skeletal muscle differentiation and development and its multiple functional domains, 
provide potential sites for mediating the adhesive cell-matrix interactions and cytoskeletal 
reorganization (Tkachenko E., 2005; Fig.10). 
 
 
 
 
In metastatic tumour cells, SDC1 and SDC3 exhibit two cellular routes: an intracellular 
one involving internalisation of the PG and its occasional translocation into the nucleus 
(Dobra et al., 2003) and an extracellular one involving surface shedding. The former 
Figure 9. Schematic overview of the putative molecular functions of SDC2 and SDC4. Either individually or through a putative 
cooperation, SDC-2 and SDC4 strongly impact on cytoskeletal dynamics through phosphorylation events taken place in the 
cytoplasmic tail. SDC4 cytoplasmic phosphorylation also activates distinct mTOR-Akt survival pathways and endocytic 
recycling of the two PGs partly contributes to this function, as well as activation of analogous signal transduction pathways. 
 
Figure 10. Schematic overview of the putative molecular functions of SDC3. The role of this PG are much less 
known/studied, but even here a putative cooperation with SDC4 and possibly other syndecans has been proposed. HS 
chains of SDC3 may exert similar growth factor/cytokine-sequestring and ECM-linking functions as those described for the 
corresponding HS chains attached to other syndecans. ECM linkage may similarly activate the cytoplasmic tail of the PG 
and  engage the cytoskeleton, as well as other signal transduction events. In the CNS, SDC3 has been proposed to 
interact with NMDA receptor and participate in the control of neuronal signalling. Nothing is currently known about potential 
endocytic trafficking of this PG. 
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translocation routing may reflect a ‘‘functionally unrelated’’ consequence of the loss of 
cell–cell contacts upon neoplastic transformation, though the precise function of cytosolic 
and intranuclear syndecans still remains to be defined. It is similarly unknown whether 
syndecan internalisation is a spontaneous auto-removal process, or whether it is 
associated with the transformation-induced endocytosis of putative syndecan ligands. On 
the other hand, release of the extracellular syndecan ectodomain involves a well-known 
phenomenon of surface shedding driven by MT1-MMP-mediated cleavage of syndecan 
and having a potentially multivalent role. Through its activation of the Wnt signalling 
pathway syndecan shedding may contribute to the process of tumorigenic (Alexander et 
al., 2000) and, via this participation in signal transduction events and the activation of the 
avβ3 integrin (Beauvais et al., 2004), it may stimulate cell migration (Endo et al., 2003). In 
addition, highly invasive carcinoma and melanoma cells seem to produce syndecans with 
a diverse glycanation pattern, which, irrespective of shedding phenomena, confers to 
these PGs the unique ability to mediate the cells’ interaction with laminin(s) (Salmivirta et 
al., 1994; Engbring et al., 2002). Thus, differential glycosylation of cell surface HSPGs 
may provide tumour cells with an adjunct to the repertoire of their ECM interactive 
capabilities needed to accomplish optimal migrations. Glypicans may also exert 
counteracting roles during neoplastic transformation and tumour progression. The 
expression of glypicans seems to be involved in cell proliferation and migration and some 
of these proteins can play a double role acting both stimulating and inhibiting proliferation, 
in relation to tissue or cellular context (Dietrich et al.,1977). GPC1 expression is up-
regulated in pancreatic cancer cells and in breast cancer. Similarly to the situation with 
SDC1, high GPC3 expression seems to protect transformed cells from converting into a 
strongly malignant phenotype. This since mammary carcinoma cells engineered to 
overexpress GPC3 show reduced local invasiveness and develop fewer metastatic lung 
lesions in murine tumour models (Peters et al., 2003). Accordingly, indirect evidence in 
the literature suggest that in hepatocellular carcinoma, GPC3 may be released from the 
developing tumour cells during early phases of their transformation and malignant 
progression and may be absent from the poorly differentiated, metastatic cells (Fig. 11)  
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Figure 11. Schematic overview of the putative molecular functions of GPC1 and GPC3. Similarly to syndecans through their 
HS chains they are believed to sequester a variety of growth factors and additionally have been shown to also immobilize 
TGFβ and BMP antagonists and Wnt family members, thereby participating indirectly in the control of TGF and Wnt 
signalling events. There no or very few molecules that are known to specifically associate with the core proteins of these 
PGs, but their are postulated to be involved in cell-ECM interactions. Endocytosis of GPC1 has been documented and the 
PG may also act intracellularly. For unknown reasons GPC3 may promote, rather than inhibit apoptosis in certain cell types. 
 
GPC5 has recently been found to be up regulated in rhabdomyosarcomas where it seems 
to influence malignancy (Williamson et al., 2007; Fig. 12). 
 
Figure12 . Schematic overview of the putative molecular functions of the GPC5. As for most other glypicans the biological 
function of the PG is still obscure, but it is the first glypican to be discovered to be upregulated in soft-tissue sarcomas (i.e. 
rhabdomyosarcomas). Both HGF and FGF family growth factor and ECM linkage are presently the candidate functions of 
the GPC5. 
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Conversely, virtually nothing is known about the role of other, i.e. GPC2, 4 and 6 in 
tumour development. In highly aggressive neoplasia of the nervous system and in 
melanoma, NG2 seems to play a fundamental role in conferring to the cells the invasive 
and metastatic potential (Chekenya et al., 2002). In fact, if NG2-negative melanoma cells 
are transduced with NG2, their ability to give rise to lung metastasis is substantially 
increased (Burg et al., 1998). It is also expressed by a number of different types of 
tumours, including melanoma (Real et al., 1985), glioblastoma (Schrappe et al., 1991), 
chondrosarcoma (Leger et al., 1994), and myeloid leukemia (Smith et al., 1996). NG2 
appears to be important for potentiating cell motility (Burg et al., 1997,1998: Fang et al., 
1999; Eisenmann et al., 1999) and for modulating cellular responses to growth factors 
(Grako et al., 1995, 1999; Nishiyama et al., 1996b; Goretzki et al., 1999), properties which 
are critical for the proliferation and migration of both immature progenitor cells and tumour 
cells. Instead, NG2 interactions with ECM molecules regulate signalling pathways 
involved in cell proliferation and motility (Iida et al.,1995 ; Tillet et al., 2002; Fig. 13). 
Linkage of NG2 to ECM components (and its putative interaction with cell surface 
molecules) triggers cytoskeletal rearrangements (Majumdar et al, 2003) that may, in part, 
be mediated by the multi-PDZ domain adapter molecule MUPP1. In addition, PKCa-
mediated phosphorylation of the threonine residue at position 2256 of the cytoplasmic 
NG2 tail allows the clustering of the PG at filodopial tips (Lin et al., 1996a,b). 
Simultaneous molecular interactions involving the cytoplasmic portion of NG2 and the 
formation of integrin-mediated focal adhesions trigger FAK phosphorylation and down-
stream activation of Rac-1 and cdc42 to further control actin microfilament and 
microtubular dynamics in the filopodial and lamellopodial protrusions of the migrating cell 
(Majumdar et al, 2003). These signalling cascades also involve activation of the kinase 
Ack-1 and a FAK-independent activation of ERK.  
 
 
 
 
 
 
 
  
  
 
 
Figure 13. NG2 involvment in regulation of adhesion, migration and invasion of tumour cells. During cancer cell migration, 
seems to be the underpinning for the FAK/p130cas-mediated activation of cdc42 and Rac1 implicated in the control of 
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microtubular dynamics. NG2 may also modulate the activity of certain integrins, in particular α3β1 and α4 β1 and electively 
link to ECM components, where the primary ligand is collagen type VI. 
 
The proposed tumour stimulating action of the NG2 is associated with its ability to function 
as a docking receptor for PDGF-AA (Stallcup, 2002) and various members of the FGF 
family (Cattaruzza et al., 2008). It may be potentiate the effect of growth factors by 
sequestering them at the cell surface and presenting them to their respective signalling 
receptors. Also matrix metalloproteinases (MMPs) are another ligand for NG2. In 
particular membrane-type 3 matrix metalloproteinase (MT3-MMP) forms a complex with 
NG2 that is critical for the ability of melanoma cells to degrade and invade a type I 
collagen-containing matrix (Iida et al., 2001). However, NG2 is also strongly implicated in 
the neoangiogenic process by sequestering angiostatin and supporting pericyte sprouting 
and tubular formation (Goretzki et al., 2000; Chekenya et al., 2002; Ozerdem et al., 2003; 
2004; Virgintino et al., 2007a; b) but the precise mode by which NG2 confers to tumour 
cells invasive and metastatic capabilities and, thereby, influences progression of tumours 
remains to be fully clarified. By virtue of its direct association with the actin cytoskeleton 
(Lin et al., 1996a; b; Fang et al., 1999; Barritt et al., 2000), a possible mechanism by 
which NG2 may affect tumour development and spreading is by promoting the tumour 
cells interplay with neighbouring host cells and ECM constituents. This function is believed 
to be exerted through, on one hand, an association of the NG2 with galectin-3 and 
integrins α3β1 and α4β1 (Iida et al., 1992; 1995; Eisenmann et at., 1999; Fukushi et al., 
2004), and on the other by assisting tumour cells in their linking to specific collagens, such 
as collagen type VI (; Stallcup et al., 1990; Nishiyama and Stallcup, 1993; Burg et al., 
1996; 1997; Tillet et al., 1997; 2002), produced endogenously or by the stromal 
compartment. In mesenchymal tumours collagen type VI transcription seems to be down-
regulated as a consequence of neoplastic transformation (Schenker and Trueb, 1998), 
whereas it is upregulated in the stromal tissue of breast cancer lesions (Iyengar et al., 
2005). Remodelling of collagen type  VI-containing matrices may contribute to the 
acquisition of drug resistance in ovarian tumours (Sherman-Baust et al., 2003), probably 
because it counteracts the drug-activated apoptotic machinery of the cells and triggers 
intracellular signals responsible for cell survival (Rühl et al., 1999a; b). It remains, 
however, unknown whether Col VI also promotes tumour spread and metastasis formation 
and, if so, through which mechanisms.  
 
1.10. Membrane PGs in sarcoma metastasis 
In the last years extensive progress has been made in the identifying of molecules 
implicated either cell-ECM interactions, cell-cell interactions or in adhesion and motility 
mechanism (Akiyama et al.1993, Yamada et al., 1995). PGs and integrins are molecules 
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that are fundamentally important for mediating cell adhesion (Akiyama et al.1993, Albeda 
et al., 1990, Hynes et al., 1992). In fact PG binding sites are often expressed in close 
proximity to integrin binding domains within ECM molecules or cell surface adhesion 
molecules suggest that cellular recognition of the ECM might involve the formation of 
receptor clusters on the plasma membrane that include both cell surface PGs and 
integrins. It has been seen that NG2 controls tumour progression in melanoma and 
sarcoma (Benassi et al., 2009) locally and distantly by accentuating growth responses, by 
mediating the tumour cell-host microenvironment interaction, by promoting 
neoangiogenesis, and by conferring enhanced drug resistance. In fact NG2 is highly 
expressed in melanoma lesions and metastases of soft-tissue sarcomas patients show a 
>5-fold increase in the expression of NG2 when compared to the primary lesion(s) of 
these individuals (Benassi et al., 2009). Since NG2 proteoglycan was identified as cell 
surface ligand for collagen type VI (Stallcup et al., 1990; Midwood and Salter, 2001) we 
went to consider as interaction of NG2-collagen type VI was implicated in tumour 
progression. To address this possibility we have examined the NG2 and collagen type VI 
expression patterns in primitive and secondary lesions of sarcoma patients and addressed 
the cellular and molecular mechanisms through which the interaction of these molecules 
may propagate tumorigenesis and induce metastasis formation. Instead, the only one 
evidence about HSPG involvement in sarcoma tumour is given by GPC5 in 
rhabdomyosarcoma. It has been seen that amplification of GPC5 in rhabdomyosarcoma 
and its expression plays a role in tumour development (Williamson et al, 2007). GPC5 
might be used for therapeutic intervention, as a potential modulator of multiple growth 
factors, therapies that reduce the function of GPC5 could affect multiple tumorigenic 
pathways. Instead potential immunotherapeutic strategies have recently been described 
involving the use of GPC3 (Motomura et al., 2006) and GPC5 might represent a similarly 
appropriate target for this approach in rhabdomyosarcoma. 
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2.1. Cell culture 
Estabilished sarcoma and melanoma cell lines (Table 4) A375 cell line were obtained from 
ATCC and whereas a number of sarcoma cell lines were estabilished from surgical 
specimens obtained from sarcoma patient tretated at CRO Institute (Centre of Oncologic 
Reference, Aviano (PN), Italy). All cells  were cultured in DMEM (Dulbecco’s modified 
Eagle’s medium; 1.0 g/L Glucose; BioWitakker) supplemented with Pen/Strep, 2mM L-
Glutamine and 10% (v/v) fetal bovine serum (FBS, Gibco).  
 
Table 4. List of sarcoma cell lines used 
CELL LINE HYSTOTYPE 
SK-UT-1 LEIOMYOSARCOMA (uterus) 
SKL-MS-1 LEIOMYOSARCOMA (vulva) 
Saos2 OSTEOSARCOMA (bone) 
143B OSTEOSARCOMA (bone) 
MG63 OSTEOSARCOMA (bone) 
SW982 SYNOVIAL SARCOMA (synovium) 
HT1080 FIBROSARCOMA (connective tissue) 
MES-SA UTERINE SARCOMA (uterus) 
Hs913T FIBROSARCOMA (metast.to lung) 
RD RHABDOMYOSARCOMA (muscle) 
SAR 91266 FIBROSARCOMA 
A204 RHABDOMYOSARCOMA (muscle) 
DMR-SN-8.4.98 LEIOMYOSARCOMA 
NTI-LMS-5 LEIOMYOSARCOMA 
 
GCT 
PLEOMORPH  
MALIGNANT HISTIOCYTOMA 
SJRH30 RHABDOMYOSARCOMA (muscle) 
NTI-LS-1 LIPOSARCOMA 
NTI-LMS-3 LEIOMYOSARCOMA 
NTI-MFH-3 MALIGNANT FIBROHISTIOCYTOMA 
NTI-PNS-1 PNS SARCOMA 
NTI-LMS-3 LEIOMYIOSARCOMA 
NTI-MFH-1 MALIGNANT FIBROHISTIOCYTOMA 
NTI-MS-1 MULLERIAN SARCOMA 
SW872 LIPOSARCOMA 
NTI-LS-2 LIPOSARCOMA 
NTI-LS-3 LIPOSARCOMA 
NTI-LS-4 LIPOSARCOMA 
NTI-OS-1 OSTEOSARCOMA 
NTI-LMS-6 LEIOMYOSARCOMA 
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The sarcoma cell line GCT was provided by Istituto Zooprofilattico Sperimentale della 
Lombardia e dell’Emilia Romagna (Brescia, Italy) and maintained in DMEM medium (1.0 g/L 
Glucose) with 10% FBS. Non-manipulated, mock-transfected and NG2 stably transduced 
(Burg et al., 1998) murine B16-F10 melanoma cells were grown in DMEM with 10% FBS. 
Twenty-one-mer siRNA probes against human NG2, scrambled versions of these probes 
were synthesized with the Dicer siRNA Generation kit (Gene Therapy Systems Inc., San 
Diego, CA) as previously described (Cattaruzza et al., 2009). In addition siRNA probes 
against NG2 and integrin β1 were obtained through Ambion (Austin, TX). Human Umbelical 
Vein endothelial cell (HUVEC) were isolated from umbelical cords  (ARCI Ospedale S.Maria) 
as previously described (Balconi et al., 1986; ). HUVEC were manteined till 4 passage in 
medium M199 (Gibco) supplemented with Pen/Strep, 20% FBS, 50mg/ml heparin (Sigma) 
and 50ng/ml endothelial cell growth (ECG, Sigma). Human Iliac Venous and Arterial 
Endothelial Cells (HIAEC), Human Pulmonary Artery Endothelial Cells (HPAEC) and Human 
Coronary Artery Endothelial Cells (HCAEC) were cultured in Endothelial Cell Growth Medium 
MV (Cambrex) supplemented with Pen/Strep, 2%FBS, 0.1ng/ml ECG, 1µg/ml Hydrocortison 
and 1ng/ml basic Fibroblast Factor . Human Lymphatic Endothelial Cells (HLEC; ScienCell) 
were cultured in Endothelial Cell Medium (ECM, ScienCell) supplemented with Pen/Strep, 
5%FBS and ECG. All the cells were incubated at 37°C  in a humidified atmosphere of 5 % 
CO2. 
2.2. RNA extraction  
Total RNA was extracted from sarcoma cells lines and peripheral blood lymphocytes 
obtained after informed consent using TRIzol (Invitrogen) according to the manufacturer’s 
instructions. To control no DNA contamination was performed a PCR with primers for RLP41 
on reverse-transcribed without RNA as substrate.  
 
2.3. Real time quantitative PCR 
Quantitative PCR reaction was performed on cDNA by ABI PRISM 7900 Sequence Detector 
and ABI PRISM 7900 HT Fast Real-Time PCR System (PE Applied Biosystems), with 
TaqMan technology. Expression of target genes GPC1, GPC2, GPC3, GPC4, GPC5, GPC6, 
SDC1, SDC2, SDC3, SDC4 and CSPG4 was quantified using TaqMan Low Density Array 
(TLDA) based on the fluorogenic 5’ nuclease assay (Fig. 14). The assay were chosen 
among thr TaqMan Gene Expression Assay library (Table 5) and the TLDA was  runned on 
ABI 7900 HT Fast Real-Time PCR System.  
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       Table 5. Gene expression library list 
Gene Symbol Assay ID 
GPC1 Hs00157805_m1 
GPC2 Hs00415099_m1 
GPC3 Hs00170471_m1 
GPC4 Hs00155059_m1 
GPC5 Hs00270114_m1 
GPC6 Hs00170677_m1 
SDC1 Hs00896423_m1 
SDC2 Hs00299807_m1 
SDC3 Hs00206320_m1 
SDC4 Hs00161617_m1 
CSPG4 Hs00426981_m1 
 
An equal amount of input cDNA (100ng) was used per reaction and loaded in one of the 
eight sample-loading port of the card. The amount of target gene was normalized to an 
endogenous housekeeping gene 18S rRNA and relative to cDNA from human mesenchymal 
stem cells (hMSC), choosen as sample calibrator.  
 
 
 
Figure 14. .a)TaqMan Low Density Array; b) ABI 7900 HT Fast Real-Time PCR System.  
 
Expression of target genes, NG2 (CSPG4) and α3(VI) chain (COL6A3) was quantified using 
TaqMan Gene Expression Assays (Applied Biosystems) according to manufacturer’s 
protocol and using Assay-on-demand primers with codes Hs99999905_m1 for GAPDH, 
Hs00426981_m1 for NG2 and Hs00365098_m1 for COL6A3. PCR mixture contained 1.25 µl 
Target or Endogenous Reference Assay Mix 20X, 22.2ng DNA diluted in 11.25 µl of distillate 
water, 12.5 µl TaqMan Universal Master Mix 2X (Applied Biosystems) in a 25 µl final reaction 
volume. Following activation of UNG (Uracil-N-Glycosylase) for 2 min at 50°C and of 
AmpliTaq Gold DNA polymerase for 10 min at 95°C all  genes were amplified by 45 cycles for 
15 seconds at 95°C and for 1 min at 60°C. For calcu lation of gene expression we used 2-∆∆CT 
sample-loading 
48 reaction wells 
connected to 
each 
 sample-loading 
port 
spotted with  
TaqMan Gene  
a)                                                 b) 
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comparative method. The amount of NG2, COL6A3  was normalized to an endogenous 
reference (GAPDH) and relative to a calibrator (cDNA from healthy lymphocytes). 
 
2.4. DNA extraction 
Clones genomic DNA was prepared using InstaGeneTM Matrix 6% (Bio-Rad Laboratories) 
according to the manufacturer’s instructions. DNA quality extraction was done by PCR 
amplifying the housekeeping gene RLP41 Forward primer GGAGGCCACAGGAGCAGAAA 
and Reverse primer TGTCACAGGTCCAGGGCAGA.  
 
2.5. Plasmids and Transfection 
143B osteosarcoma cells were stably transfected both with pDisplay GPC-6-HA/pDisplay 
empy vector and with pEGFP-C1-GPC6/ pEGFP-C1 empty vectors. pDisplay vector 
contained human cDNA of Glypican-6 Hemagglutinin A (HA)-tagged. The expression vector 
pDisplay (Invitrogen) containing ORF cDNA of GPC-6 and Hematoglutinin A (HA )-tagged 
and the box for G418 resistence (Geneticin/Neomycin). It was gently provided by Guido 
David (University of Leuve-CME). pEGFP-C1-GPC-6 vector was obtained cloning GPC-6 
cDNA in pEGFP-C1 by PCR reaction with two specific primer- restriction- adapters 3’-SmaI 
CAGATCCTCTTCTGAGATGAG and 5’ BclI- GAGGGTGATCAGCCCAGCCGGCCAGATCC. 
The PCR product was cut with BclI (New England Biolabs) and SmaI (New England Biolabs) 
and purified from the agarose gel using the “QIAquick Gel Extraction Kit” (QIAGEN) in 
according to manifacture’s. pEGFP-C1 vector (BD Biosciences) was linearized with BclI and 
SmaI for cDNA GPC-6 ligation using T4 DNA Ligase (Biolabs; Pashley C et al., 2003). In 
order to select stable transfected cells it was necessary to determine the right concentration 
of G418. For this reason a dose-response curve was performed in 143B cells in response to 
different concentration of G418, from 100ug/ml up to 1mg/ml. The lower concentration which 
kill all cells in two weeks was 500 µg/ml. Cells were transfected with pDisplay-GPC6 vector, 
pEGFP-C1-GPC-6 and their respective empty vectors using metafectene-pro (Biontex, 
Germany) in according to the manufacturer’s instructions. After twenty-four hours from 
transfection the cells were trypsinized and seeded on 10cm dish at low density (6000cells 
per dish) and growth in selection condition with G418 (500 µg/ml) for two weeks. For 
selecting monoclonal cells the colony were picked with p200 Gilson and were expanded; 
clones were screened by PCR amplification for Amp gene Forward primer 
GTGTCGCCCTTATTCCCTTT and Reverse primer GGCACCTATCTCAGCGATCT. The 
positive clones were also screened for GPC -6 expression wither by real time PCR and 
immunonostaining and FACS. 
Sarcoma cell lines were also transiently or stably transfected using Lipofectamine Plus as a 
delivery vehicle with a plasmid containing either the cytoplasmic tail and membrane-spanning 
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domain of the PG, or the membrane spanning domain plus the entire ectodomain. Human 
NG2 cDNA clones B, C and D (Plusckhe et al.,1996) were cut with XhoI and SacI, SacI and 
HindIII, HindIII and BamHI, respectively. These fragments were ligated and inserted into the 
pEGFP-N1 vector (Clontech Laboratories Inc.), and the sequence of the entire insert 
comprising bases 4030-7216 of the CSPG4 sequence reported with the NCBI accession 
number X96753 was verified by automated DNA sequencing. Dominant-negative-like mutant 
cells named NG2cyto were generated by transient transfection of the cells previously stably 
transduced to express cells with the 3’-end-directed NG2 siRNA probe 1279 to specifically 
abrogate the constitutively produced NG2 and spare the transduced deletion construct. 
Dominant-negative mutants named NG2extra were generated by stable transfection of the 
same cell lines with a GFP-plasmid containing the entire extracellular portion and the 
transmembrane domain of human NG2. For this purpose, NG2 cDNA clones H, G and F 29 
were cut with XhoI and ApaI, ApaI and BamHI, BamHI and HindIII, respectively, and inserted 
between the XhoI and HindIII sites in pEGFP-N1 vector (BD Biosciences). Total cDNA from 
A375 melanoma cells was used as the template to amplify the sequence corresponding to 
nucleotides 2230-5025, the fragment was inserted into a pGEM-T vector (Promega), and its 
sequence verified by automated DNA sequencing. The construct was then subcloned into the 
pEGFP-N1 expression vector containing fragments H, G and F as described above (BD 
Biosciences). Cells stably transfected with this plasmid were transiently transfected with a 5’-
end-directed NG2 siRNA probe (Cattaruzza et., 2008) to differentially eliminate the 
endogenous NG2 without affecting the transduced deletion construct. In both types of 
dominant-negative mutants, relative levels of expression of the full-length endogenous NG2, 
following siRNA knock-down, versus transduced truncated NG2 were determined at the 
mRNA level by quantitative real-time PCR as described above and by FACS and 
immunoblotting (Cattaruzza et al., 2009). Deletion constructs lacking different segments of the 
putative collagen-binding region of the ectodomain were as previously described (Burg et al., 
1997; Tillet et al., 1997). 
 
2.6. Western blotting 
Cells were solubilized in RIPA lysis buffer (Tris-HCl (pH 7.4) 50mM, NaCl 150mM, P-40 1%, 
Na-deoxycholate 0.5%, SDS 0.1%, EDTA 2mM, leupeptin 50µM, aprotinin 2µg/ml, soybean 
trypsin inhibitor 2µg/ml, pepstatinNa3VO4 1µg/ml, NaF 1mM, Pefabloc SC 0.8mM) after 
collection from a 90mm dish and double washing with PBS1X. The protein content in the 
different samples was determined using Bradford method (Bradford et al., 1976; Zor et al., 
1995). Surnatant (400 µl) were incubated overnight in -20°C with 2.5 volum es of cool 100% 
methanol. The precipitate was washed in cool 100% acetone and recovered for dissolving in 
sterile water and 20µl of concentrated media were denatured with 2X sample buffer (final 
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concentration Tris-HCl (pH 7.4) 0.065M, Glycerol 10.5%, SDS(10%) 21%, Bromophenol 
Blue(0.05%) 6.5% ). Lysates (30 µg) and surnatant concentrated were fractionated by SDS–
PAGE using 8% polyacrylamide gels, based upon the expected molecular weight. 
Supernatant of stable cell lines were collected after 24 hours of culture incubation in DMEM 
serum free and concentrated utilizing methanol protocol (Burbach et al., 2003). The resolved 
proteins were blotted to a nitrocellulose membrane (Amersham Pharmacia) by semi-dry 
electric transfer, and the membranes were blocked for 1 h in TBS buffer (20 mM Tris–HCl pH 
7.6, 137 mM NaCl) containing 5% blotting-grade non-fat milk. Membranes were incubated 
with primary antibodies diluted in milk with 0.1% Tween 20 overnight. The following 
antibodies were used: anti-HA High Affinity (1:2000; clone 3F10, Roche Diagnostics); anti-
GFP (1:5000; Fitzerald); anti-actin (1:3000; Sigma Aldrich). Membranes were washed three 
times in TBS for 5 min each and then incubated in TBS containing the appropriate 
horseradish peroxidase conjugated anti-mouse, anti-rat or anti-rabbit secondary antibodies 
for 1 h. The membranes were washed three times for 5 min each in TBS with 0.1% Tween 20 
and then processed for enhanced chemiluminescence detection according to the 
manufacturer's instructions (Amersham Life Science). Equal loading of samples was 
confirmed by probing for actin. 
 
2.7. Preparation of ECM substrates 
Coverlips and inserts traswell were coating with different ECM molecules (20 µg/ml). 
Fibronectin, laminin-1 and vitronectin were dissolved in 0.05 M bicarbonate buffer pH 9,6 
(Spessotto et al., 2001) for coating the surfaces for about 1 hour a room temperature and 
37°C for vitronectin. Coverslips and the upperside of transwell were washed three time with 
PBS. Collagen molecules were dissolved in 0.02N of acetic acid for coating coverslips and 
inserts transwell for about 1 hour at room temperature and left them to dry underflow 
continuous, in according to the manufacturer’s instructions. Whether upper side and under 
side of transwell were coated with Matrigel (BD Biosciences, San Jose, CA). In the latter 
case, Matrigel was diluted in cold serum-free DMEM medium at a concentration of 0.5 mg/ml 
and 50 µl/well dispensed on top of the porous membrane. The Matrigel solution was then 
incubated for 1 hr at 37°C to form a semisolid thin  gel across the membrane. 
 
2.8. Immunostaining 
Sarcoma cells line were seeded in 24 well coated glass coverslips. Cells were fixed with 4% 
paraformaldehyde (PFA) for 15 min and then were washed three times with PBS for 10 
minutes. Exogenous GPC6 was detected with anti-HA rat (1:300; Roche) or anti-GFP rabbit 
(1:500; Sigma), in PBS with 10% NGS and 0.1% Triton-X 100 at 4°C overnight. Binding of 
primary antibody was revealed with specific FITC-co
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antirabbit Alexa 488 (1:100; Invitrogen), in PBS with 10% NGS and 0,1 % Triton-X 100. F-
actin was visualized with TRITC conjugated phalloidin (Sigma) for 15 minutes at room 
temperature. Endosomes was detected using anti-Rab5 (abcam; 1:100), in PBS with 
10%NGS and 1%Triton-X 100 overnight at 4°C and foll owed by incubation with secondary 
antibody TRITC conjugated antirabbit (1:100, Sigma) in PBS with 10% NGS and 1%Triton-X 
100 for 1 hour at room temperature. NG2 was visualized using anti-NG2 monoclonal 
antibody, in PBS with 10% NGS, 0.1%Triton-X 100 overnight at 4°C followed by incubation 
with TRITC conjugated antimouse (1:100), 10%NGS and Tricton-X 100 for 1 hour at room 
temperature. Nuclei were counterstained with Hoechst 33258 (Sigma) for 20 minutes a room 
temperature. Samples were washed three times in PBS and mounted with Mowiol 4-88 
(Calbiochem-BD Biosciences) supplemented with 2.5 mg/ml DABCO anti-fading reagent 
(Sigma-Aldrich). 
 
2.9. FACs analysis 
FACS analyses were carried out with the anti-NG2 PE-conjugated antibody 7.1 (Beckman-
Coulter) and anti-GPC6 goat antibody (R&D) for 40 minutes at 4°C. The secondary antibody 
conjugated-PE was left 30 minutes at 4°C. For negat ive controls, IgG isotypes were used at 
the same concentration as the primary antibody. Immunosorting of NG2+ and NG2- sarcoma 
cells was accomplished MACS-based magnetic bead separation using either the anti-NG2 
antibody 9.2.27 (Millipore Corporation) or one of our recently generated anti-NG2 monoclonal 
antibodies mAb 2161D3 followed by incubation with goat anti-mouse IgG microbeads 
(Milteny Biotech, Inc). Relative efficiency of the immunosorting procedure and approximate 
yield of NG2+ cells was on average 23.4% for SW982 cells, 13.6% for HT1080 cells, 28.4% 
for SK-LMS-1 cells and 18.7% for SKUT-1 cells. 
 
2.10. Cell proliferation assays 
 For cell growth curves, cells were seeded in triplicate in 6-well culture plates at a density of 1 
x 105 cells per well. After 24, 48, 72, 96, hours. Cell number and cell viability were determined 
daily using a Burker chamber (Beckman Coulter-Z2) and the trypan blue dye exclusion test. 
 
2.11. Adhesion and spreading assays 
Adhesion of siRNA treated and untreated cells to various purified ECM components was 
examined using a previously detailed cell adhesion assay denoted CAFCA (Centrifugal 
Assay for Fluorescence-based Cell Adhesion; Spessotto et al., 2001), which allows for both 
qualitative and quantitative parameters of cell-substratum adhesion to be established. For 
the assessment of cell attachment  to purified ECM molecules, sarcoma cells were seeded in 
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serum-free medium and allowed to adhere to different substrates for 30 minutes and fixed 
with 4% of PFA. Subsequently the cells were washed three time with PBS and 
immunostained. Assessment of cell adhesion to ECM molecules was carried out in multiple 
independent adopting 15-20 different representative fields of the substrate with discernable 
matrix deposits. The cells were counted under epifluorescence Nikon eclipse E600 
microscope  
 
2.12. Cell Migration assays 
FATIMA assay (Fluorescence-Assisted Transmigration, Invasion and Motility Assay) was 
performed using transwell insert (Falcon HTS FluoroBlock™ Inserts, BD) for evaluating cells 
migration in response to ECM molecules and a monolayer of endothelial cells. Scratch assay 
was performed using ibidi Culture-Insert (Ibidi Culture System) for evaluating cells motility. 
Cell migration, invasion and transendothelial assays were carried out using a modified 
version of FATIMA  (Fluorescence-Assisted Transmigration, Invasion and Motility Assay;  
Spessotto et al., 2001). Transwell inserts (Fig. 15) with 8 µm pore size membranes were 
coated 20 µg/ml using purified ECM molecules as previously described.  
 
 
 
Figure 15. Schematic overview of transwell insert 
Cells were previously labeled with Cell Tracker ORANGE and FAST DiTIM (Molecular 
Probes) in according to the manufacturer’s instructions. 100000 cells /ml in 200µl DMEM 1% 
FBS were seeded on membrane into the upper compartment coated with ECM)molecules. 
The lower chamber contained DMEM 10%. After 16 hours the cells were fixed in PFA 4% 
and counted using inverted fluorescent Nikon Eclipse TS 40x. In several experiments 
invasion assays were performed counting nine fields for each transwell (Fig. 16) In others 
the percentage of transmigrated and “nonmigrated” cells was assessed using the 
SPECTRAFluor microplate fluorometer (TECAN Group, Maennedorf, Switzerland). 
Haptotactic migration and invasion assay of siRNA treated and untreated cells in response to 
purified EMC molecules and Matrigel was examined by real-time videomicroscopy. It was 
done with an inverted phase contrast microscope (Leica) equipped with an on-stage mini-
chamber providing routine incubation conditions (37°C, 5% CO 2). Phase contrast images 
0.8mm 
Upper chamber 
Microporus membrane (8µm) 
 
Lower chamber 
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were taken in 5-minutes intervals, contrasted digitally and exported into conventional image 
analyses software for elaboration and presentation.  
 
 
Figure 16.The scheme shows the methodology for counting migrated cells. 
 
Transendothelial assays were performed realizing and endothelial monolayer on the 
under side of transwell. 300000 endothelial cells for ml previously stained with Orange 
CellTracker were seeded on the upper side and left in incubator for about 2 hours. 
Transwells were again reverse in wells of 24 well plate filled with 800µl of endothelial 
medium. The confluence of the endothelial cell monolayers was reached after 72 hours 
(Fig. 17).  
 
Figure 17. The monolayer of endothelial cells was verified inverted fluorescent Nikon Eclipse TS (40x). 
 
100000 sarcoma cells per ml were previously labeled with Green CellTracker (Molecular 
Probes) and seeded into the insert. Kinetic curves of migrated cells was performed 
counting cells in different times using inverted fluorescent microscope. 
Material and Methods 
 
 36 
Scratch assays was performed using Ibidi Culture System for making linear scratches of 
200 µm thick. Cells were seeded into each well at concentration of 3x105 cell/ml in 70 µl 
DMEM 1% FBS and were incubated at 37° and 5% CO 2 C. After about 22 hours the cells 
reached confluence and the insert was removed by using sterile tweezers with the result 
of two defined monolayer with a scratch of 200 µm thick (Fig. 18). 
 
             
Figure 18. Steps for the Wound healing assays using Ibidi Culture System. 
 
The wounds are observed using inverted phase contrast microscopy. Images were taken 
using 10x magnification at regular intervals over the course of 12–24 hours. Images were 
analyzed by digitally drawing lines (using Adobe Photoshop) averaging the position of the 
migrating cells at the wound edges. The cell migration distance was determined by 
measuring the width of the wound divided by two and by subtracting this value from the 
initial half-width of the wound (Valster et al., 2005). 
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Results 
 
 36 
3.1. Constitutive PG mRNA pattern 
In order to understand the implication of PG surface profiles in the malignancy traits of 
established cell lines and cells isolated in the our laboratory a screening was performed 
on 31 sarcoma cells for defining the constitutive pattern of NG2, glypican and syndecan. 
PG surface were revealed in each sarcoma cell were showed to have a different and 
particular PG pattern (Table 6). 
Table.6. PG Expression pattern in sarcoma cells. 
Cells CSPG4 GPC1 GPC2 GPC3 GPC4 GPC5 GPC6 SDC1 SDC2 SDC3 SDC4 
GCT + +     + +  + + 
HT1080 + +   + +  + + + + 
Hs913T nd1 +      +  + + 
NTI-FS-1 + +    + + + + + + 
MES-SA 
 + +   +  +  +  
SK-LMS-1 + +     + +  + + 
SK-UT-1 + +    +  +  + + 
NTI-LMS-1 
         + + 
NTI-LMS-3 nd +    + + +  + + 
NTI-LMS-5 
 +   +  + + + + + 
NTI-LMS-6 +    + +   + + + 
NTI-LMS-8 nd +  nd +  nd + + + + 
SW872 nd +     + +  + + 
NTI-LS-1 + +      + + + + 
NTI-LS-2 
        +   
NTI-LS-3 
 +    nd + nd  + + 
NTI-LS-4 + +   +  + + + + + 
NTI-LS-5 + +      + + + + 
NTI-MFH-1 nd +     + +  +  
NTI-MFH-3 nd +     +   + + 
NTI-MFH-4 +       + +  + 
NTI-MS-1 
   + + + + + + + + 
143B  + + +  + + + + + + + 
MG63 +       + +  + 
SAOS2 +      +  + + + 
NTI-OS-1 +  + + + + + + + + + 
RD +   + +   + + + + 
A204 nd +     + +  + + 
SJRH30 + + + + + + + + + + + 
SW982 (+)2 +    + + +  + + 
NTI-PNS-1 nd +    + + +  + + 
(1 nd: not determined; 2 (+): to confirm) 
 
This first qualitative analysis were showed an average of 5-8 PGs surface in fibrosarcoma 
cells. NG2, GPC1, SDC1, SDC3 e SDC4 were always expressed whereas GPC2 and 
GPC3 were not revealed and GPC4 was expressed only in HT1080 cells. An average of 
6-7 PGs surface were identified in leiomysarcoma, SDC3 and SDC4 were always 
expressed whereas GPC2 and GPC3 were not detected; NTI-LMS-1 cells express only 
two genes (SDC3 and SDC4). In liposarcoma cells, GPC2, GPC3 and GPC5 were not 
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expressed and GPC4 and SDC2 were expressed respectively only in NTI-LS-4 cells . An 
average of 4-5 PGs surface was detected in malignant hystocitoma. GPC2, GPC3, GPC4 
and GPC5 were not expressed and NG2 was detected only in NTI-MFH-4 cells. In 
osteosarcoma hystotype 10 PG on total of 11 was identified in 143B and NTI-OS-1 cells 
even if have got a different genetic profile; whereas NG2, SDC2 and SDC4 were always 
expressed. In rhabdomyosarcoma, NG2, SDC2 and SDC4 were always expressed 
whereas 11 PGs were detected in SJRH30 cells. 
Sarcoma cells were tumor of mesenchymal origin and their PG expression were 
compared to cDNA of hMSC cells (calibrator sample) after normalizing to endogenous 
housekeeping gene 18S rRNA. The relative expression of surface PGs were showed in 
Fig. 19 with the exception of GPC2, GPC3, GPC5 and SDC1 because they were not 
exhibited in calibrator sample. 
 
  
CSPG4 GPC1 GPC2 GPC3 GPC4 GPC5 GPC6 SDC1 SDC2 SDC3 SDC4 
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HT1080                       
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Figure 19. Relative gene expression of sarcoma cells grouped in hystotypes. TaqMan low-density arrays results: gene 
expression level down-regulate ⁬ddd  , up-regulate ⁬ddd  or unchanged  ⁬ddd in comparison to hMSC as sample calibrator; 
⁬ddd indicate that PG was not expressed, ⁬ddd indicate that PG was not expressed in both cells and sample calibrator, ⁬ddd 
indicate that was not possible to calculate relative expression. 
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The comparison of the PGs relative expression showed different PGs pattern respect to 
reference sample in fibrosarcoma cells, in fact all PGs were down regulated in HT1080 
cells whereas NG2, GPC1 and SDC4 were up regulated in NTI-FS-1 cells. In 
leiomyosarcoma cells all PGs expressed are down regulate and NG2 expression was 
50% less than in the sample calibrator (data no show). In liposarcoma cells, NG2 
expression was up-regulated in NTI-LS-4 and NTI-LS-5 cells, GPC6 and SDC2 were up 
regulated respectively in NTI-LS-4 and NTI-LS-1 cells, instead the other PGs were down 
regulated in comparison to calibrator sample. In osteosarcoma cells all PGs were down 
regulated with the exception of NG2 that was up regulated in MG63 and Sa-os-2 cells 
respect to sample calibrator. 
 
3.2. Model cells with diverse pattern of surface PGs 
This preliminary screening has permitted us to identify 24 different model cells (Fig. 20) 
with diverse combinations of surface PGs. It was been found that sarcoma cells may 
constitutively and coincidently expressed  from 4 to 8 of the 11 surface PGs with the 
exception of NTI-LS-2, 143B and SRJH30 cells. 
 
Figure. 20. Overview of 24 model cells characterized by their PG profile 
 
To start to investigate the PG surface profiles as pro- and anti-tumorigenic we delineated 
strategies to modify the PG expression of 143B osteosarcoma cells by stable gene 
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transduction and by examining how these modifications affected the cells adhesive and 
migratory capabilities in response to selected ECM substrates, and endothelial 
monolayers. For this aim, 143B were stable transfected for overexpressing GPC6 that 
was chosen as a first PG to modulate since there is currently no knowledge about its 
involvement in tumor behaviour. 
 
3.3. GPC6 subcellular localization 
143B cells were stable transfected with GPC6 using pDisplayGPC6 vector or pEGFP C1-
GPC6 vector to produce overepressing cells. GPC-6 N-terminal was fused respectively 
with HA or eGFP as reporter genes. GPC6 overexpression (143BGPC6+) was detected 
by qPCR (data not shown), immunostaining and Western blotting (Fig. 21).  
 
Figure 21 . 143B GPC6 transfected with pEGFPC1GPC6 vector . A). GPC6 detection by immunostaining using anti-GFP 
and the nuclei were counterstained with Hoechst 33258 and examinated by fluorescent microscope; B). GPC6 expression 
together with GFP protein, the fusion product was about 100KDa; 143B mock (control) and two different selected clones 
143B clone 109, 143B clone 111; actin was shown as control loading. 
 
A detail analysis of 143B GPC6 overexpressing cells by confocal laser microscopy and 
flow cytometry confirmed the localization of GPC6 on surface (Fig.22). 
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.  
 
Figure 22. GPC-6 localization on membrane surface. A). GPC6-HA detection using immunostaining with anti-HA and nuclei 
was counterstained with TO-PRO-3. B). GPC6 overexpression was detected using anti-GPC6 in comparison with control.  
 
3.4. Effect of GPC6 overexpression on cell morphology  
In order to investigate the relationship between GPC6 overexpression and cell shape, the 
143B GPC6 overexpressing cells were stained with phalloidin-TRITC to reveal an actin 
filaments organization (F-actin) (Fig. 26).  
 
 
Figure26. Cells morphology was observed with phallodin staining that highlighted actin filament protrusion. GPC6 was 
detected with anti-HA and nuclei were counterstained with Hoechst 33258 (60x).  
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143B GPC6 overexpressing cells have showed a markedly different cellular morphology 
than the vector control cell line. Morphological changes induced by GPC6 overexpression 
could be associated with changes in the organization of their actin filaments. In particular, 
phalloidin staining revealed that 143BGPC6 overexpressing cells showed protrusions 
similar to fillopodia/lamellipodia. Moreover it also possible to observe a more 
concentrations of F-actin in the attachment sites of the cells to the substrate, suggesting a 
more pronounced focal contact formation. 
 
3.5. Changes of PG profiles upon modulation of GPC6 overexpression 
Modulation of surface PG profile was demonstrated in tumour cells (Timar et al., 1990). To 
that end, for analyzing forced expression of GPC6 in 143B cells we also investigated the 
relative expression of PGs surface compared to 143B vector control cells.(Fig. 27) 
Figure 27. PGs surface modulation by qPCR. The level of relative expression was calculated using 143b vector control cells 
as calibrator sample after normalizing to endogenous housekeeping gene 18S rRNA 
 
It was observed that the PG surface profile in 143B GPC6 overexpressing cells was 
modified when compared to control vector cells. First of all 143BGPC6+ showed an 
evident over expression of GPC6 (about 500 fold) respect to 143B vector control. GPC1, 
GPC2, GPC4 and SDC1 had a little increased of expression respect to control. Whereas it 
was interesting to observe an evident over expression of GPC5, about 570 folder than the 
control. The misexpression GPC6 on a given background of surface PGs brought an 
evident modulation of the other PGs. 
 
3.6. Role of GPC6 in cell-ECM interactions 
Modulation of surface PGs profile and changes in morphology of 143B overexpressing 
cells had led us to investigate how those alterations could affect the adhesive capabilities 
of this cells. A preliminary screening was made analyzing the spreading of 143BGPC6 
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overexpressing cells on different ECM molecules (fibronectin, vitronectin, laminin-1, 
collagen type III and V). Cell spreading was evaluated observing the distribution of actin 
filaments staining (F-actin) of 143BGPC6+ cells in response to ECM substrates and 
uncoated surface (as a control; Fig. 28). 
 
 
 
A 
B 
C 
D 
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Figure 28. Adhesion and spreading ability of 143BGPC6+ cells on different molecules substrates: collagene type III (A), 
collagene type V (B), vitronectin (C), fibronectin (D), laminin-1 (E), uncoated surface (F). The percentage of adhesion 
143BGPC6+ was compared to 143B vector control. Valuation of cell adhesion was performed counting about 1000 cells in 
several fields (average of percentage of cells adhesion to the substrate). The assay was made in triplicate (* p<0,05; ** 
p<0,01) 
 
The behaviour of 143B overexpressing cells could be concatenated to different surface 
PGs profile. 143B GPC6 overexpressing cells showed different ability to adhere on each 
ECM molecules in particular on laminin-1 and collagene III substrates. Moreover the 
spreading of 143BGPC6+ cells was lowest than the vector control cells on uncoated 
surface. It was interesting to look the lacking of stress fibres in both cells on vitronectin 
and uncoated substrates.  
F 
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3.7. Haptotactic migration of 143BGPC6 overexpressing cells  
Migration ability of 143BGPC6 overexpressing cells was evaluated in response to different 
ECM molecules (fibronectin, laminin-1, vitronectin and collagen type III and V). The upper 
side of transwell was coated with ECM molecules and the migration of cells was estimated 
after 16 hours to ensure that migration could not be affected from cell proliferation. The 
migration of 143BGPC6 overexpressing cells was compared with 143B vector control cells 
(Fig. 29) 
 
Figure 29. Number of cells migrates in response to ECM molecules. The assay was performed using HTS fluoroblock 
transwells. Cells were previously labelled with OrangeCell Tracker and the number of cells migrates were counted in nine 
different fields, using fluorescent inverted microscope (40x). The experiments were made in duplicate (histograms shows an 
average of experiments in duplicate, * p<0,05). 
 
 
There was not visualized difference in cells migration but the motility of 143BGPC6 
overexpressing cells in response to ECM molecules was resulted to be significantly 
different on collagene III and on vitronectin substrates. 
 
3.8. Kinetics of cell motility displayed by 143BGPC6 overexpressing cells  
To study the motility of 143B GPC6 overexpressing cells was performed a wound healing 
assay (or scratch assay) using Ibidi Culture System as previously described in material 
and methods. The wounds were observed using inverted phase contrast microscopy. 
Images were taken at regular intervals 0, 3, 5, 7, and 24 hours (Fig.30) and analyzed for 
realizing kinetics curve. 143BGPC6+ cells motility was compared to 143B vector control 
cells  
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Figure 30. Kinetics migration of 143BGPC6+ cells and control cells. (A). The trend of migration was detected using inverted 
phase contrast microscopy (10x). Scratch assay was made in duplicate and the kinetic curves were showed the same trend;  
(B). Kinetic curves of 143BGPC6+ and control cells (averages was made by measuring the width of the wound in 5 different 
points of captured images using draw line of adobe Photoshop). 
 
GPC6 overexpression in 143B cells has permitted the closure of the wound more quickly 
than the control cells. Moreover it was possible to observe how the cell motility was 
independent from cell proliferation. 
A 
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3.9. Intracellular fate of transduced GPC6  
Modified expression of GPC6 has been observed in 143BGPC6+ cells which could be 
attributable to shedding or to enhanced endocytocis of the PG. For detecting an eventual 
proteolysis of GPC6 a preliminary analysis was made going to look the GPC6 expression 
level in culture medium. The culture medium of 143BGPC6 overexpressing cells was 
concentrate (clone 109 and 111) and the protein lysate was used as control (Fig. 31). 
 
 
Figure 31. Western blotting of GPC6-GFP protein levels in surnatant cultured cells. A). In order to loading surnatant: 
concentrated of 143B, 143BGPC6+ clone1, 143BGPC6+ clone2, 143BGPC6GFP+ clone 109, 143BGPC6GFP+ clone 111 
and protein lysate of 143B GPC6GFP+ clone 111 B). Ponceau S staining shows protein loading 
 
 
 
From this first approach it was possible to observe the lacking of GPC6 protein in culture 
medium showing that GPC6 recycling could have another way. Since GPI-anchored 
protein were internalized and transported in recycling endosomes the fate of GPC6 was 
studied analysing the endosome vesicles with Rab proteins (Rab-5; Fig.32). 
 
A 
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Figure 32. Colocalization of GPC6 and Rab-5 (arrow). There was not Rab-5 expression in cells where GPC6 has ceased to 
be delivered. Images were taken by fluorescent microscope (60x). 
 
Preliminary analyses showed a correlation between expression of GPC6 and Rab-5 
suggesting a high endocytotic activity of GPC6. Rab-5 was not revealed in 143B that not 
expresses GPC6. This hypothesis will be validated through confocal laser microscope. 
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3.10. NG2 and collagen type VI expression in sarcoma cells 
Since NG2 and collagen type VI cooperate in tumour progression (Stallcup et al., 1990) 
we have studied how NG2-collagen type VI interactions may influence the behaviour of 
sarcoma cells. We have screened the expression of α3(VI) (collagen type VI) and NG2 in 
sarcoma cells by qPCR and FACs for looking if there was a relationship between NG2 
and collagne VI expression in sarcoma cells. A375 melanoma cells were used as 
reference (Table 8) 
 
Table 8. Expression of NG2 and collagene VI in sarcoma cells 
 
Different expression of NG2 was detected in cells, SW872 cells were showed a high 
expression of NG2 (99,4%) than the other cells. High expression levels were detected 
also in SK-LM-S-1 (88,5%), MG63 (83,6%), NTI-OS-2 (81,2%) cells. Low levels of NG2 
were observed in NT-LS-2 (0,9%), NT-LS-3 (1,7%), NTI-MFH-2 (1,0%) and NTI-LMS-4 
(2,3%) cells. Collagen type VI was expressed in SK-LM-S-1, SK-UT-1, GCT, HT1080, 
SW872 and NTi-LMS-1 cells. High expression levels of collagene VI were detected in NTI-
FS-1 cells. 
 
3.11. NG2 involvement in the adhesion and spreading of sarcoma cells on 
collagen type VI substrates  
In order to investigate NG2 involvement in sarcoma cells adhesion on collagen type VI we 
performed adhesion assays using CAFCA methodology which allows a quantitative 
analysis of cell-substrate interactions. We have chosen sarcoma cells which exhibited 
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diverse constitutive levels of NG2 as NTH-LS-2, NTI-FS-1, 143B, NTI-OS-2, SK-LMS-1 
and SW872 (Fig. 33). 
 
Figure 33. Relative levels of cell adhesion of different sarcoma cells . The comparisons the levels of adhesion with high 
NG2 expressing cells were found to be significantly higher than those of the low expressing ones (p<0,001) 
  
The assay showed a clear relationship between NG2 expression levels and the ability of 
the cells to bind to collagen type VI substrate. Adhesion of sarcoma cells to collagen type 
VI was looked to be largely commensurate to their constitutive surface levels of NG2. 
For further understanding if NG2 was really involved the binding to collagne type VI, 
sarcoma cells were NG2 silenced using RNAi; representative levels of NG2 knockdown by 
RNAi as determined by flow cytometry using the anti-NG2 antibody 7.1 (Cattaruzza et al., 
2009; Fig.34). CAFCA assay was performed using either NG2 deprived cells or untreated 
cells on collagen type VI and collagen type I substrates (as a control). 
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Figure 34. Cell adhesion after silencing of NG2. A). NG2 silenced cells were verified by flow cytometry. An exemplified for 
the synovial sarcoma cell line SW982. Largely comparable abrogation levels were obtained in the other sarcoma cell lines; 
B). Comparing of adhesion of siRNA treated and untreated cells on different matrices quantified using CAFCA system; 
p<0,01 C). Quantification of CAFCA system. Images were captured using camera connected phase-contrast microscope 
(40x); p<0,01. 
 
Comparison of adhesion of siRNA treated and untreated cells to collagen type VI 
underlined that NG2 abrogation significantly reduces both adhesion and spreading of the 
cells on this substrate and this effect seems rather specific for this collagen since little or 
no inhibition was seen on other representative ECM components. 
Since the sarcoma cell lines used for this study were a mixed population of NG2 positive 
and NG2 negative cells, SK-UT-1 cells has immunosorted with MACS-based magnetic 
beads separation (Cattaruzza et al., 2009). Relative efficiency of the immunosorting 
B 
C 
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procedure and approximate yield of NG2+ was an average 18,7% for SK-UT-1 cells. 
CAFCA assay was performed for SK-UT-1 NG2+ and SK-UT-1 NG2- immunosorted cells 
on collagen type VI, fibronectin and collagen type I substrates (Fig. 35). 
 
 
Figura 35. Adhesion of SK-UT-1 NG2+ and NG2- cells imnusorted. A). Representative views of attachment and spreading 
of NG2+ and NG2- cells. Cells on the indicated substrates as revealed by phalloidin-Texas red staining. B). Corresponding 
quantitative analysis of cell adhesion to the same substrates; * p<0,01. 
Comparing the adhesion of two subpopulations on collagen type VI has underlined 
different binding and spreading of NG2+ and NG2- cells on substrates. Whereas adhesion 
to collagen type I and fibronectin was not distinguishable. 
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3.12. NG2 involvement in the movement of sarcoma cells on collagen type VI 
substrate 
Since NG2 influences the migration of tumour cells we tested migration of sarcoma cells 
with different surface levels of NG2 on different ECM substrates (Fig. 36). 
 
 
Figure 36. Relative levels of cell migration of different sarcoma cell lines exhibiting diverse constitutive levels of NG2 
expression. In several pair-wise comparisons the levels migration of high NG2 expressing cells were found to be 
significantly higher than those of the low expressing ones (*, p<0,001) 
 
It was interesting to note again sarcoma cells showed a migration ability in response to 
collagen type VI substrates that closely correlated with the endogenous levels of NG2 
surface expression. In order to examine if NG2 was really involved in migration, sarcoma 
cells were NG2 silenced with siRNA. We have chosen to analysis the haptotactic 
migration of treated and untreated SK-LMS-1 cells because they had a high migration 
percentage and easily detectable. The migration of SK-LMS-1 silenced and untreated 
cells were monitored on collagen type IV, collagen type VI and collagen type I (as a 
control; Fig 37). 
 
Figure 37. Haptotactic migration of treated siRNA and untreated cells on substrates. Selectively reduced haptotactic 
movement of RNA-mediated NG2 knockdown. 
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A 3-dimensional migration assay was performed by coating the transwell upper side with 
Matrigel. Collagene type VI was embedded in polymeric collagen type I substrates and 
Matrigel (Fig. 38). 
. 
 
 
Figure 38. Reduced migration of sarcoma cells in response to Collagene VI after NG2 knockdown when examined in a 3D 
setting. Haptotatic migration was detected using SPCTRAfluor fluorometerI (p<0,001). Images were captured using camera 
connected to confocal microscopy 
 
 
 
 
Also in this case RNAi-mediated NG2 silencing strongly compromised invasion of cells to 
move through collagene VI-containing Matrigel, in comparison to their counterpart. 
We examinated the interaction between sarcoma cells and different endothelial cells 
(HUVEC, HLEC, HCAEC and HIAEC). Transendothelial migration was performed using 
SK-UT-1 NG2+ and NG2- immunosorted. The kinetics of transmigration was examinated 
in different times (0, 2, 5, 8, 24 and 30 hours; Fig. 39).  
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Figure 39. Transmigration assay. A). Kinetics of migration of two NG2 SK-UT-1 subpopulation; the assay was performed in 
duplicated; B). SK-UT-1 NG2+ and NG2- immunosorted cells were previously labelled with GreenCell Tracker. The 
endothelial monolayers were labelled with OrangeCellTracker.. 
 
The results showed a different transmigration behaviour of SK-UT-1 NG2+ and NG2- 
immunosorted cells only on HUVEC but not in others endothelial monolayer. It was 
interesting to observe that the percentage of two SK-UT-1 subpopulation migrates in the 
others endothelial monolayer less (about 10%) than SK-UT-1 NG2+ (about 25%) on 
HUVEC monolayer. 
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Cell surface PGs are multifunctional molecules with roles in adhesion and growth factor signalling 
and are gradually emerging as key regulators of tumour progression. There are currently 11 
membrane-bound PGs known in man and a certain number of them have been proposed to 
influence tumorigenesis by acting upon local tumour growth and/or by contributing to the metastatic 
processes. Increased or de novo induced expression of both secreted and cell surface-associated 
PGs may be a characteristic traits of invasive tumours solid. However paradoxically, these 
macromolecules often exhibited counteracting tumour growth-promoting and tumour progression-
inhibiting functions depending on the tumour type in which they are mixepressed (Nurcombe et al., 
1993; Cattaruzza et al., 2008). Nevertheless aberrant distribution of PGs observed in various 
tumours has incited a wealth of investigations on their potential diagnostic-prognostic, as well as 
therapeutic role. Several of these macromolecules are assuming important roles as prognostic 
factors and few are approaching the clinics. Given the dual tumour-promoting and tumour-
suppressing role that cells surface PGs may play it is interesting to investigate whether different 
combinations of cells surface PGs actually synergize to promote tumour progression or act 
antagonistically to impede tumour growth and metastasis formation. The mode by which certain 
cell surface PGs may participate in the tumorigenic process has in some cases been extensively 
investigated (Fico et al., 2007; Sanderson et al.,2007; Munusue et., 2007; Williamson et. al, 2007) 
several have been found to exert a potential antineoplastic role by interfering with cell surface 
components regulating cell growth and maintenance of a differentiated phenotype. Since there is 
no information about surface PGs may affect the malignancy in sarcomas we have performed a 
preliminary screening for determining the surface PG profile in established cell lines and cells 
isolated from patients by qPCR and immunocitochemistry. This screening has allowed us to 
establish 24 surface PG pattern in sarcoma cells with an average of 5-8 PGs preserved on each 
cell type with the exception of 11 PGs expresses in SJRH30 rhabdomyosarcoma cells, 10 PGs 
detected in 143B and NTI-OS-5 osteosarcoma cells at the transcript level and only 1 surface PG 
expressed by NTI-LS-2 leyomiosarcoma cells. Literature data and our preliminary observations 
suggest that given combinations of surface PGs may diversely dictate the behaviour of cancer cells 
during distinct phases of tumour progression,. In fact our surface PG screening show how the 
same surface PG profile have been identified in cells belong to different hystotypes which could be 
in direct relation to the aggressive behaviour of the cells. Characteristically, in progressing tumours 
two patterns emerged: loss or neoexpression of surface PG depending on the initial expression 
pattern of the cell type of origin (Timar et al, 2002). Altered expression of surface PGs was 
detected in sarcomas respect with hMSC cells which could be the putative cell of origin of these 
tumours. In this study we aimed the asserting hypothesis that well-defined cell surface PG profiles 
may influence in specific way cancer cell motility, spreading and host microenvironment 
interactions. The relative expression of surface PGs in 143B osteosarcoma cells showed down 
regulation of all PGs. Till to day there are no notice about GPC6 implications either in cell-ECM 
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interactions or in behaviour motility of cells. For these reasons 143B cells were stable transfected 
for overexpressing GPC6 showed a modulation of relative expression of all surface PGs with 
changes of GPC1, 2, 3, 4, 5, 6 and SDC1 expression compared to control. Nevertheless, the 
GPC5 transcript level is highly up regulated in 143B overexpressing cells (about 670 fold) respect 
to control in which it is relatively absent. GPC6 overexpression induces morphological modification 
in 143B cells which are seen as changes in the organization of actin filaments containing 
protrusions similar to fillopodia/lamellipodia. Similar morphological changes have been observed in 
SDC4 overexpressing cells (Velleman et al., 2007). Moreover GPC-1 and SDC4 are able to 
regulate cell proliferation (Velleman et al., 2007) and could be correlated with a reduction of 
proliferation of 143B GPC6 overexpressing cells. The overexpression of GPC6 triggers with an 
increase of motility cells in monodimensional assay which could be in relationship with cytoskelatal 
reorganization revealed by immunoassaying. The effect of GPC6 on cell motility has been 
confirmed from Cell Migration Knowledgebase (CMKB; http://www.cellmigration.org) database 
where it is showed how MCF-10A cells GPC6 silenced migrate lower than untreated cells. Since 
either cell-cell interactions or cell-ECM interactions play a pivotal role in many of the phenomena of 
tumour progression we are going to examinee how cellular contacts with the ECM are mediated via 
membrane-bound proteoglycans (Silbert et al., 2003). HS chains have particular confidence to bind 
to collagen type III and -V, fibronectin, vitronectin and laminin-1. So we investigated 143B GPC6 
overexpression ability to spread and to respond to these ECM molecules. In fact overexpression of 
GPC6 in 143B cells is linked to a reduction of behaviour adhesion on collagene III and also on 
uncoated substrates, greater adhesion ability on laminin-1 substrate than control cells. Moreover a 
greater spreading of 143B GPC6 overexpressing cells are observed on all ECM molecules with the 
exception of vitronectin where they have showed lower adhesion ability and lack of stress fibres. 
Nevertheless 143B GPC6 overexpressing cells has a greater invasion ability in response to 
collagene type III than vector control cells and this is  unchanged in response to collagene type V 
and reduced further in response to vitronectin. In particular the spreading ability and the lower 
invasion ability of the transduced cell line by overexpressing GPC6 on different ECM molecules 
could be correlated by surface PG profile modulation. SDC4 overexpression allowed cell spreading 
on vitronectin with formation of focal adhesion (Echtermeyer et al., 1999) explaining the adhesive 
behaviour of 143B GPC6 overexpressing and control cells on this substrate. Nevertheless cell-
ECM interactions are mediated also by integrins that transmit signals from the ECM into the cells 
and vice versa [90-91] so it will be interesting to observe the existence of collaboration between 
surface PGs, in particular HSPGs and integrins (Juliano et al., 1993; Woodhouse et al., 1997). 
Preliminary observation reveals a partial disappearance of GPC6 from surface of 143B GPC6 
overexpressing cells over time. GPI-anchored proteins are usually associated with sphingolipid- 
and cholesterol-rich plasma membrane domains. Such enriched domains may exist either as small 
phase-separated "rafts" or, when associated with caveolin-1 (Cav-1), form flask-shaped 
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plasmalemmal invaginations called caveolae, which are involved in signal transduction and special 
forms of non-clathrin-dependent endocytosis mediated by Cav-1-containing endosomes, also 
called caveosomes (Drab et al., 2001). GPC1 has been associated with lipid rafts, caveolae, 
caveosomes, or endosomes transporting cargo from the plasma membrane to the Golgi. Using 
anti-Rab5 as a marker for late endosomes (Barbero et al, 2002), colocalization with GPC6 are 
seen in small vesicles in cytoplasm. This observation will be validated with more detailed analysis 
using confocal laser microscope. 
To dissect the molecular mechanisms that may govern the neoplastic behaviour of sarcoma cells 
with different relative surface levels of the above glypicans we will select the model cells that 
through the combination of our in vitro and in vivo assays have emerged as those with the 
strongest and poorest aggressive phenotype and on these we are performed combined antibody 
array- and immunoblotting-based phosphorylation analyses (adopting platforms provided custom 
by Kinexus Bioinformatic Corporation, Canada).  
 
The idea that NG2-positive cells may be particularly aggressive was sustained by comparing the in 
vivo behaviour of NG2-positive and NG2-negative subsets implanted into immunodeficient mice: 
the former sarcoma cells grew into a defined mass more rapidly and more extensively than the 
latter ones (Cattaruzza et al., 2009). This observation is consistent with our in vitro findings 
showing sustained anchorage-independent growth of NG2+ cells and recalls the potential influence 
of the PG in the control of cell survival and proliferation. In fact, in a separate, recent study from 
our group we demonstrate that NG2 profoundly affects mitogenic responses of sarcoma cells to 
FGF family members (Cattaruzza et al., 2008). However, since some of the NG2+ cells 
investigated here failed to engraft and grow in nude mice, the pro-tumorigenic role of NG2 may not 
be restricted to a mere control of cell proliferation. Conversely, we hypothesize that high surface 
levels of NG2 may confer a more malignant behaviour in sarcoma cells by controlling multiple 
facets of the tumourigenic process. Analyses of the in situ distribution of the primary ECM ligand of 
NG2 revealed that up regulation of the NG2 in neoplastic cells of primary sarcoma lesions was 
accompanied by a corresponding augmented host synthesis and deposition of the collagen within 
the lesion (Cattaruzza et al, 2009). It seems that an overabundance of the collagen in the host 
microenvironment did not seem to constitute an effective prognostic/predictive factor. A restricted 
expression of Collagen type VI in the tumour stroma was also consistent with previous 
observations indicating that mesenchymal tumours may loose the expression of the collagen upon 
neoplastic transformation (Schenker and Trueb, 1998). Our present data support this notion and 
show that only a few of the sarcoma cell lines examined in this study displayed detectable levels of 
Collagene VI transcription and translation. Anyway high levels of Collagen type VI deposition in 
NG2-rich metastatic lesions suggested to us that the previously reported NG2-collagene type VI 
molecular interaction could play a crucial role in tumour cell-host microenvironment interplays, not 
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only during local growth but also during the dissemination and homing phases to reach the putative 
metastatic sites. We examinated the interactions of NG2- and NG2+ sarcoma cells with collagen 
type VI and other ECM molecules. To support this hypothesis sarcoma cells were NG2 abrogated 
by RNAi and immunosorted for NG2 expression were found to exhibited a rather elective impaired 
ability to adhere and migrate on purified collagene type VI. These findings confirmed that the NG2 
was able of mediating tumour cell adhesion and migration on Collagene type VI substrates with a 
direct interaction with the collagen and largely precluded that the NG2 acted solely as a modulator 
of the function of collagen-binding integrins (in our case of the α2β1 integrin; Chatterjee et al., 
2008). Furthermore, these data strongly supported the notion that enhanced growth and metastatic 
behaviour of NG2-expressing sarcoma and melanoma cells could be directly mediated by a local 
interaction with collagen type VI present within the tissues/organs infiltrated by metastasizing cells 
or overproduced and secreted within the tumour lesions by stroma-forming cells. These preliminary 
linear findings corroborated the role of the NG2-ollagene type VI interplay in the potential 
regulation of tumour cell spread. NG2 may represent a unique, independent prognostic factor in 
several types of soft-tissue sarcomas in which its relative levels of expression in primary lesions 
are additionally capable of predicting the future occurrence of post-surgical metastases. Further 
multicenter studies are now in progress to establish whether NG2 may be proposed in the routine 
clinical practice and in which sarcoma types, else than those examined herein, it may be used as a 
metastasis predicting factor. 
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